Clinical Medicine and Diagnostics

Clinical Medicine and Diagnostics is a peer-reviewed journal publishing papers of significance in all areas of medical sciences. Articles include original research papers, reviews and short research communications. Submissions of basic and clinical research are both considered.

Hany Lashen

Editorial Board Member of Clinical Medicine and Diagnostics

Associate Professor, University of Sheffield, UK

Research Areas

Reproductive Endocrinology, Obesity in Relation to Reproduction and Fetal Growth and PCOS

Education

2000Doctorate of MedicineBirmingham University
1987P.L.A.BGeneral Medical Council, UK
1982M.BAin Shams University

Membership

Royal College of Obstetricians and Gynaecologists (R.C.O.G)
British Medical Association (B.M.A)
Medical Defence Union (M.D.U)
European Society of Human Reproduction and Embryology (ESHRE)
Birmingham and Midlands Obstetrics and Gynaecology Society
North of England Obstetrics and Gynaecology Society

Publications: Journals

[1]  Baigent A, Lashen H. Ovarian hyperstimulation syndrome in a patient treated with tamoxifen for breast cancer. Fertility and Sterility, 2011; 95:2429 e5-e7.
[2]  Jones GL, Palep-Singh M, Lwsfwe WL, Balen AH, Jenkinson C, Campbell MJ, Lashen H. Do South Asian women with PCOS have poorer health related quality of life than Caucasian women with PCOS? A comparative cross sectional study. Helath Qual Life Outcomes, 2010; 8;149-152.
[3]  Lashen H. Role of metformin in the management of polycystic ovary syndrome. Therapeutic advances in Endocrinology and metabolism. 2010;1:117-128.
[4]  Roberts AL, Lashen H. Tibolone as a hormone replacement in women with endometriosis after bilateral oophorectomy. Int J Gynaecol Obstet 2010; 111: 183.
[5]  Kelly CJ, Stenton SR, Lashen H. Insulin like growth factor binding protein 1 in PCOS: a systematic review and meta-analysis. Hum Reprod Update (Epub ahead of print) July 2010.
[6]  Moores KL, Keriakos RH, Anumba DO, Connor ME, Lashen H. Management challenges of a live 12-week sub-hepatic intra-abdominal pregnancy. BJOG. 2010;117:365-8.
[7]  Bonnett T and Lashen H. A case of acute post-laparoscopy bowel hypermotility and treatment with hyocine butylbromide. Journal of Perioperative Practice 2009; 19:436-7.
[8]  Bayley TM, Slade P, Lashen H. Relationships between attachment, appraisal, coping and adjustment in men and women experiencing infertility concerns. Human Reproduction 2009;24:2827-37.
[9]  Ghobadi C, Amer S, Lashen H, Lennard MS, Ledger WL, Rostami-Hodjegan A. Evaluation of the relationship between plasma concentrations of en-and zuclomiphene and induction of ovulation in anovulatory women being treated with clomiphene citrate. Fertil Steril 2009;91:1135-40.
[10]  Stevenson TL, Lashen H. Empty follicle syndrome: the reality about a controversial syndrome, a systematic review. Fertility Sterility. 2008;90:691-8..
[11]  Slade P, O'Neill C, Simpson AJ, Lashen H. The relationship between perceived stigma, disclosure pattern, support and distress in new attendees at an infertility clinic. Human Reproduction. 2007;22:2309-17.
[12]  Mohamed KA, Davies WA, Lashen H. Dynamics of pituitary down-regulation and ovarian response to controlled stimulation in in vitro fertilisation cycles. Fertility Sterility. 2007;87:433-5.
[13]  Mohamed KA, Davies WA, Lashen H. Antimullerian hormone and pituitary gland activity after prolonged down-regulation with goserelin acetate. Fertility Sterility. 2006;86:1515-7.
[14]  Mohamed KA, Davies WA, Lashen H. Effects of gonadotrophin-releasing hormone agonist and antagonist on steroidogenesis of low responders undergoing in vitro fertilisation. Gynecol Endocrinol. 2006;22:57-62.
[15]  Birch MP, Lashen H, Agrawal S, Messenger AG. Female pattern hair loss, sebum excretion and the end organ response to androgens. British J of Dermatology. 2006;154:85-89.
[16]  McIlveen M, Lok D, Pritchard J, Lashen H. Modern embryo transfer catheters and pregnancy outcome. Fertility Sterility. 2005;84:996-1000.
[17]  Reeves L, Lashen H, Pacey A. Endometriosis affects sperm-endosalpengeal interaction. Human Reproduction. 2005;20:448-51.
[18]  Mohamed K, Davies WAR, Allsop J, Lashen H. Agonist "flare-up" versus antagonist in the management of poor responders undergoing in vitro fertilisation treatment. Fertility Sterility. 2005;83:331-5.
[19]  Lashen H, Fears K, Sturdee D. Obesity is associated with increased risk of early and recurrent miscarriage: matched case control study. Human Reproduction. 2004;19:1644-6.
[20]  Cheong Y.C, Abdullahi H, Lashen H, Fairlie F. Can formal education and training improve the outcome of instrumental delivery? Eur J Obs Gyn Reprod Biol. 2004;113:139-44.
[21]  Jones, GL, Benes K, Clark TL, Denham R, Holder MG, Haynes TJ, Mulgrew NC, Shepherd KE, Wilkinson NH, Singh M, Balen A, Lashen H, Ledger W. The polycystic ovary syndrome Health-related questionnaire (PCOSQ): a validation. Hum Reprod. 2004;19:371-7
[22]  Elliot J, Connor M, Lashen H. The value of outpatient hysteroscopy in diagnosing endometrial pathology in postmenopausal women with and without hormone replacement therapy. Acta Obstet Gynaecol Scandinavica. 2003;82:1112-9.
[23]  Lock D, Prichard J, Lashen H. Successful treatment of empty follicle syndrome by triggering endogenous LH surge using GnRH agonist in an antagonist down-regulated IVF cycle. Hum Reprod 2003;18:1116-22.
[24]  Lashen H, Fear K, Sturdee D. Trends in the management of breech presentation at term; experience in a district General Hospital over a 10 year period. Acta Obstet Gynaecol Scandinavica 2002;81:1116-1122.
[25]  Lashen H, Afnan M, McDougall L, Clark P. Prediction of over-response to controlled ovarian stimulation in intrauterine insemination programme. Hum Reprod 1999;14:2751-2754.
[26]  Lashen H, Afnan M, Kennefik A. Early resort to ovarian stimulation improves the cost-effectiveness of the donor insemination programme. Hum Reprod 1999;14:1983-1988.
[27]  Lashen H, Afnan M, Sharif K. A controlled comparison of ovarian response to controlled stimulation in first generation Asian women vs. white Caucasians undergoing in vitro fertilisation. BJOG 1999;106:407-409.
[28]  Lashen H, Ledger L, Lopez-Bernal A, Barlow D. Poor responders to ovulation induction: is proceeding to in vitro fertilisation worthwhile? Hum Reprod 1999;14:964-969.
[29]  Lashen H, Ledger W, Bernal A, Barlow D. Extremes of body mass index do not adversely affect the outcome of superovulation and in vitro fertilisation. Hum Reprod 1999;14:712-715.
[30]  El-Gendy M, Holder R, Lashen H, Sharif K, Affifi Y, Lenton W, Afnan M Reducing the dose of gonadotrophin-releasing hormone agonist (GnRHa) on starting the ovarian stimulation; effect on ovarian response and in vitro fertilisation outcome. Human Reproduction. 1998;13:2382-2385.
[31]  Lashen H, Ledger W., Lopez-Bernal A, Evans B, and Barlow D. Superovulation with a high gonadotrophin dose for in vitro fertilisation: is it effective? Journal of Assisted Reproduction and Genetics. 1998;15:438-443.
[32]  Lashen H, Afnan M. Manipulating the gonadotrophin dose in controlled ovarian hyperstimulation for IVF and its effect on ovarian response. The Egyptian Journal of Fertility and Sterility. 1998; 2:31-36.
[33]  Sinclair L, Morgan C, Lashen H, Afnan M, and Sharif K. Nurses performing embryo transfer: the development and results of the Birmingham experience. Human Reproduction. 1998;13:699-702.
[34]  Sharif K, Afnan M, Lashen H, El-Gendy M, Morgan C, Sinclair L. Is bed rest following embryo transfer necessary? Fertility Sterility. 1998;69:478-81.
[35]  Sharif K, El-Gendy M, Lashen H, Afnan M. Age and basal follicle stimulating hormone as predictors of in vitro fertilisation outcome. British Journal of Obstetrics and Gynaecology. 1998;105:107-112.
[36]  Sharif K, Afnan M, Khalaf Y, Bilalis D, Lashen H. Ultrasound prediction of follicular volume during ovulation stimulation. Middle East Fertility Society Journal. 1997;2:53-56.
[37]  Lashen H, Ledger W, Davies WAR, Smith R. Oocyte release in luteinized unruptured follicle with a second dose of hCG. Middle East Fertility Society Journal. 1996;3:226-229.
[38]  Lashen H, Ledger W. Management of poor responders in IVF. Hum Reprod [letter] 1999;14:1919.
[39]  Lashen H, Ledger W. Effect of agonist dose on in-vitro fertilisation. Hum Reprod [letter] 1998;13:2973-2974.

Publications: Books/Book Chapters

[1]  Lashen H. (2010) Tubal Sterilisation. Chapter 10. In The Fallopian Tube in Infertility and IVF Practice. Ledger W, Tan SL, Bahathiq AOS (eds.). Cambridge University Press.
[2]  Lashen H. (2006) Unexplained Pelvic Pain. Chapter 12. In Chronic Pelvic Pain. TC Li and WL Ledger (eds.). Taylor and Francis Group, London and New York. P 183-195.
[3]  Lashen H. (2007) Investigations for infertility. Obstetrics Gynaecology and Reproductive Medicine. 17:211-6.
[4]  Li TC, Lashen H, Adam I, Wong YM. (2006) The Management of Rectovaginal Endometriosis. In Chronic Pelvic Pain. TC Li and WL Ledger (eds.). Taylor and Francis Group, London and New York. P61-74.
[5]  Lashen H. (2004). Normal Conception. Chapter 52.1 in Obstetrics and Gynaecology: An evidence-based text for MRCOG by Luesley and Baker (ed). Edward Arnold (Publishers) Limited, London. P561-565.
[6]  Lashen H. (2004). Female infertility. Chapter 52.2 in Obstetrics and Gynaecology: An evidence-based text for MRCOG by Luesley and Baker (ed.). Edward Arnold (Publishers) Limited, London. P 566-573.
[7]  Lashen H. (2004). Male infertility. Chapter 52.3 in Obstetrics and Gynaecology: An evidence-based text for MRCOG by Luesley and Baker (ed.). Edward Arnold (Publishers) Limited, London. P 574-578.
[8]  Lashen H. (2004). Assisted Reproduction. Chapter 52.4 in Obstetrics and Gynaecology: An evidence-based text for MRCOG by Luesley and Baker (ed.). Edward Arnold(Publishers) Limited, London. P 579-587.
[9]  Lashen H. (2003) Use of LHRH agonists in polycystic ovary syndrome. Reviews in Gynaecological Practice. 3, 127-31.
[10]  MCQs and Short Answer Questions for MRCOG. An aid to revision and self-assessment. Luesley and Baker (ed.) Edward Arnold (Publishers) Limited, London.
[11]  Lashen H. (2004). Investigations for infertility. Current Obstetrics and Gynaecology. An update 14:269-276.
[12]  Lashen H. (2002) Polycystic ovary syndrome. Insight 2002 Women's Health: Important developments in primary care. Chris Barclay (ed.) APS publishing. UK.
[13]  Lashen H. (2001). Investigations for infertility. Current Obstetrics and Gynaecology, 11, 4, 239-244.
[14]  MRCOG: Part 2 MCQs Clinical Obstetrics and Gynaecology. K Sharif and J Jordan. Saunders (eds.), London, UK. I compiled 30 general Obstetrics and Gynaecology questions.